Boehringer Ingelheim announced that Combivent Respimat (ipratropium bromide and albuterol) inhalation spray is now available.
Combivent Respimat is a propellant-free inhaler that produces a slow-moving mist for the treatment of chronic obstructive pulmonary disease (COPD). It is a combination of ipratropium, an anticholinergic agent, and albuterol, a short-acting β2-agonist, and is indicated for use in patients on a regular aerosol bronchodilator who continue to have evidence of bronchospasm and who require a second bronchodilator.
Combivent Respimat was developed in response to the Montreal Protocol, an international treaty requiring the phase-out of inhalers that use chlorofluorocarbons (CFCs) as propellants, such as Combivent MDI. Combivent Respimat uses a spring mechanism to release the medication, rather than a propellant, so it does not release CFCs.
Combivent MDI will be available until mid-2013. However, as of July 2013, Combivent Respimat will be the only Combivent product available.
For more information call (800) 243-0127 or visit www.Combivent.com.